Skip to content
Tablet Allopathic

Macipah 10 mg tablet

Generic: Macitentan

Company: UniMed UniHealth Pharmaceuticals Ltd.. Prices are as listed on BestinMeds; your pharmacy price may differ.

Strength10 mg
PackBox of 10: 1500.00 taka

Reviewed by: not listed yet. Source: not listed yet.

Last updated September 7, 2024.

Compare

Same generic, same strength

Sorted by price per tablet. Ask your pharmacist before you switch brands.

Macitentan 10 mg tablets

Prices as listed on BestinMeds.

1 brand listed
Macipah, box of 10 (this medicine)150.00 taka per tablet

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250
Medicine guide

About this medicine

What this medicine is for, how to take it, and what to watch for.

Read the full Macitentan guide

Indications

Pulmonary arterial hypertension Macitentan is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I ) to reduce the risks of disease progression and hospitalization for PAH. Effectiveness was established in a long-term study in PAH patients with predominantly WHO Functional ... Read more Macitentan is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I ) to reduce the risks of disease progression and hospitalization for PAH. Effectiveness was established in a long-term study in PAH patients with predominantly WHO Functional Class II-III symptoms treated for an average of 2 years. Patients had idiopathic and heritable PAH (57%), PAH caused by connective tissue disorders (31%), and PAH caused by congenital heart disease with repaired shunts (8%).

Dosage and administration

Recommended Dosage: The recommended dosage of Macitentan is 10 mg once daily for oral administration. Doses higher than 10 mg once daily have not been studied in patients with PAH and are not recommended. Pregnancy Testing in Females of Reproductive Potential: Obtain a pregnancy test in females of reproductive potential prior to Macitentan treatment, monthly during treatment and one month after stopping Macitentan. Initiate treatment with Macitentan in females of reproductive potential only after a negative pregnancy test. Pediatric Use: The safety and efficacy of Macitentan in children have not been established. Geriatric Use: Of the total number of subjects in the clinical study of Macitentan for PAH, 14% were 65 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects.

Side effects

The most common adverse reactions (more frequent than placebo by ≥3%) are anemia, nasopharyngitis/pharyngitis, bronchitis, headache, influenza, and urinary tract infection.

Precautions and warnings

ERAs cause hepatotoxicity and liver failure. Obtain baseline liver enzymes and monitor as clinically indicated. Fluid retention may require intervention. Decreases in hemoglobin. Pulmonary edema in patients with pulmonary veno-occlusive disease. If confirmed, discontinue treatment. Decreases in sperm count have been observed in patients taking ERAs.

Pregnancy and lactation

Macitentan may cause fetal harm when administered to a pregnant woman. Macitentan is contraindicated in females who are pregnant. Macitentan was consistently shown to have teratogenic effects when administered to animals. If Macitentan is used during pregnancy, advise the patient of the potential risk to a fetus. There are no data on the presence of Macitentan in human milk, the effects on the breastfed infant, or the effect on milk production. Because of the potential for serious adverse reactions in breastfed infants from Macitentan advise women not to breastfeed during treatment with Macitentan.

Clinical details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250